 |
autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc) |
|---|---|
| Trade Name | |
| Orphan Indication | Severe combined immune deficiency-X1 |
| USA Market Approval | USA |
| USA Designation Date | 2015-01-15 00:00:00 |
| Sponsor | Boston Children's Hospital;Div. of Hematology/Oncology, Karp 08215;Boston, Massachusetts, 02115 |
